Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Trial Profile

Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Oprozomib (Primary)
  • Indications Haematological malignancies; Multiple myeloma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 14 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 Feb 2018.
    • 14 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 Nov 2017.
    • 31 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top